Oxford Immunotec Global Plc (OXFD) Return on Equity ROE from the third quarter 2020 to third quarter 2019 and annually, average high and low, overall ranking from Sep 30 2020 to Sep 30 2019 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Oxford Immunotec Global Plc  (NASDAQ: OXFD)

Oxford Immunotec Global Plc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Oxford Immunotec Global Plc in the third quarter 2020?
Oxford Immunotec Global Plc recorded a cumulative net loss of $-17 million during 12 months ending in the third quarter 2020, resulting in a negative return on equity (ROE) of -8.83%.

Within the In Vitro & In Vivo Diagnostic Substances industry 6 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2020 from 0 to 2564.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2020)
III. Quarter		 (Jun 30 2020)
II. Quarter		 (Mar 31 2020)
I. Quarter		 (Dec 31 2019)
IV. Quarter		 (Sep 30 2019)
III. Quarter
Y / Y Equity Change -11.03 % -13.27 % -8.41 % -0.15 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -17 -17 -6 -2 141
Return On Equity (TTM) -8.83 % -8.15 % -3 % -0.84 % 65.3 %
OXFD's Total Ranking # 2564 # 0 # 0 # 0 # 113
Equity (TTM) in Millions 191 189 198 214 215
Seq. Equity Change 1.25 % -4.6 % -7.34 % -0.59 % -1.29 %
Seq. Net Income Change - - - - 21.53 %

Back to OXFD Management Effectiveness >> OXFD's 5 Years Annual ROE >> Compare OXFD ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 7
Sector # 223
Overall # 2564

Return On Equity Statistics
High Average Low
110.11 %
-6.36 %
-60.63 %
(Dec 31 2018)   (Sep 30 2017)





OXFD Annual Return On Equity (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016		 (Dec 31 2015)
2015
Total Equity in Millions 214 214 88 73 93
Y / Y Equity Change -0.15 % 144.22 % 20.1 % -21.28 % 52.93 %
Net Income in Millions -2 121 -33 -22 -24
Y / Y Net Income Change - - - - -
Return On Equity -0.85 % 56.44 % -37.53 % -30.63 % -26.41 %

Back to OXFD Management Effectiveness >> OXFD's 5 Years Annual ROE >> Compare OXFD ROE to its Competitors




More Return On Equity Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
OXFD's' Return on Equity at Yahoo Finance
OXFD's Roe Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for OXFD's Competitors
Subscribers only: Roe for Oxford Immunotec Global Plc's Suppliers
Subscribers only: Return On Equity for OXFD's Customers




Companies with similar Return On Equity at Sep 30 2020, within Healthcare Sector ROE

Date modified: 2026-09-08T15:10:03+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.